U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761088
Company: CELLTRION INC
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
TRUXIMA RITUXIMAB-ABBS 100MG/10ML(10MG/ML) INJECTABLE;INJECTION Prescription None No No
TRUXIMA RITUXIMAB-ABBS 500MG/50ML(10MG/ML) INJECTABLE;INJECTION Prescription None No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
11/28/2018 ORIG-1 Approval N/A Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761088s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761088Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761088Orig1s000TOC.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
02/04/2022 SUPPL-18 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761088Orig1s018ltr.pdf
05/29/2020 SUPPL-9 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761088Orig1s009ltr.pdf
12/18/2019 SUPPL-6 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s005, s006ltr.pdf
12/18/2019 SUPPL-5 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s005, s006ltr.pdf
05/23/2019 SUPPL-2 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s001s002Replacementltr.pdf
05/23/2019 SUPPL-1 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761088Orig1s001s002Replacementltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
02/04/2022 SUPPL-18 Labeling-Medication Guide Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf
02/04/2022 SUPPL-18 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf
05/29/2020 SUPPL-9 Labeling-Medication Guide Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf
05/29/2020 SUPPL-9 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761088s009lbl.pdf
12/18/2019 SUPPL-6 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf
12/18/2019 SUPPL-5 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088s005s006lbl.pdf
05/23/2019 SUPPL-2 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf
05/23/2019 SUPPL-1 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761088Orig1s001s002_Replacementlbl.pdf
11/28/2018 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761088s000lbl.pdf
Back to Top